• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "June, 2015"
 Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board
 0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted June 18, 2015

Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board

San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its [...]

READ MORE
 Nascent Biotech, Inc. Begins Toxicology Trials
 0
By Nascent Biotech
In News
Posted June 4, 2015

Nascent Biotech, Inc. Begins Toxicology Trials

San Diego, CA, June 4th, 2015 – Nascent Biotech, Inc., (OTC.NBIO) Nascent Biotech, Inc announced that it has begun toxicology trials on its primary asset Pritumumab, a monoclonal antibody [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.